Biotech
-
Getty Images
The hidden scale-out problem behind CAR-T’s growth
CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave like one reliable system. In vivo aims to eliminate the batch altogether.
By Sy Mukherjee • Sept. 1, 2026 -
Getty Images
Social anxiety drugs have been floundering in the clinic. Could Eli Lilly help tip the scales?
After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley this year.
By Alexandra Pecci • Aug. 31, 2026 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Permission granted by Argenx
Q&A // First 90 DaysA single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act.
Under its new chief, Karen Massey, Argenx is positioning its blockbuster Vyvgart to become the Keytruda of the autoimmune disease space.
By Meagan Parrish • Aug. 28, 2026 -
Getty Images
3 takeover targets in immunology
Dealmaking in the autoimmune space is thriving as biotechs chase new targets with the potential to treat more conditions.
By Kelly Bilodeau • Aug. 26, 2026 -
Getty Images
Q&AIs AI finally proving its worth in drug R&D?
A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program in oncology R&D. But will the findings apply in more therapeutic areas?
By Kelly Bilodeau • Aug. 26, 2026 -
Getty Images
Q&ALegend’s interim CEO sees a shorter path to the next era of CAR-T
Alan Bash explains how Carvykti informed the company’s strategy and what its in vivo platform still needs to prove.
By Sy Mukherjee • Aug. 25, 2026 -
Permission granted by Tyra Biosciences
Tyra’s one-drug, three-indication bet nears its first phase 2 test
What started as two neighbors trading shop talk has grown into Tyra Biosciences, a clinical-stage biotech company with a blockbuster potential pipeline.
By Alexandra Pecci • Aug. 21, 2026 -
Getty Images
Moderna and Merck’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod
A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower doses of its obesity pill.
By PharmaVoice Staff • Aug. 21, 2026 -
Getty Images
OpinionThe scientific research pharma leaders keep sharing — and why
Six industry leaders share the scientific papers they keep circulating, spanning transplants, MASH, cancer, real-world evidence and trial design.
By Kelly Bilodeau • Aug. 20, 2026 -
Getty Images
FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax
Strain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.
By Alexandra Pecci • Aug. 17, 2026 -
Sean Gallup / Staff via Getty Images via Getty Images
BioNTech’s oncology pivot comes with a new CEO
Guido Oelkers will inherit a deep cancer pipeline, declining vaccine sales and $19 billion to fund the transition.
By Kelly Bilodeau • Aug. 14, 2026 -
Getty Images
Biotech initiatives pick up as more regions race to become hubs
New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t determine where pharma builds next.
By Alexandra Pecci • Aug. 13, 2026 -
Permission granted by Image courtesy of Formation Bio
Profile // First 90 DaysFormation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’
Dr. Michael Ehlers bets AI can ease the clinical-development bottleneck — but scaling Formation Bio’s pipeline will also require human judgment.
By Alexandra Pecci • Aug. 12, 2026 -
Getty Images
Did Novo’s phase 3 flop kill the inflammation hypothesis in heart disease?
While a disappointing late-stage readout sent biotech stocks tumbling, all hope may not be lost for the emerging approach to treating cardiovascular events.
By Kelly Bilodeau • Aug. 10, 2026 -
Getty Images
FDA allows unique endpoint in rare disease study
Global regulators are allowing the company to use hospitalization as the primary efficacy endpoint in its registration trial for a rare neuromuscular disorder.
By Alexandra Pecci • Aug. 5, 2026 -
Getty Images
Three potential takeover targets in psychedelics
Lilly’s recent deal to acquire AtaiBeckley gave the field a boost, but other biotechs still need to prove their clinical and commercial potential.
By Kelly Bilodeau • Aug. 4, 2026 -
Getty Images
Genetic clues for cell therapy toxicities; Summit’s high-stakes FDA decision
Researchers have pinpointed genes linked to dangerous CAR-T cell therapy side effects, and a predictions market weighs in on Summit’s closely-watched cancer drug.
By PharmaVoice Staff • July 31, 2026 -
Permission granted by Telix Pharmaceuticals
Q&AHow Telix landed a $2.1 billion radiopharma deal with Regeneron
Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement.
By Alexandra Pecci • July 30, 2026 -
Permission granted by Caribou Biosciences
BMS and Gilead rule in the CAR-T space. Off-the-shelf developers aren’t trying to change that.
Rather than going head-to-head with approved CAR-T cell therapies, biotechs like Caribou Biosciences are positioning their drugs to fill unique market gaps.
By Kelly Bilodeau • July 29, 2026 -
Getty Images
Why 3 secretive biotechs are keeping their science close to the chest
Startups like Altos Labs are keeping pipeline details scarce to protect their ideas from competitors — but some experts say stealth only works for biotechs with deep pockets.
By Kelly Bilodeau • July 27, 2026 -
Getty Images
Lilly’s leap into psychedelics; peptides in the spotlight
Eli Lilly is extending its push in neuroscience while the FDA wrestles with controversial peptide drugs.
By PharmaVoice Staff • July 24, 2026 -
Getty Images
OpinionBiopharma challenges leaders want to tackle
Boosting public trust, delivering genuine breakthroughs and getting trials off the ground remain top-of-mind issues in the industry.
By Meagan Parrish • July 23, 2026 -
Michel Lunanga / Stringer via Getty Images
As the Ebola outbreak rages, new treatments are headed into trials. Will they work?
The strain causing the current outbreak has no approved treatments or vaccines but global organizations are rushing to change that.
By Alexandra Pecci • July 20, 2026 -
Permission granted by Banyan BioInnovations
Long days, dinners with copious alcohol, and the hunt for emerging assets in China
Why building relationships, navigating cultural nuances and preparing for different deal structures are key to investing in China’s promising drugs.
By Meagan Parrish • July 17, 2026 -
Getty Images
Biotech SpotlightThis startup thinks humans in clinical trials could become a ‘formality’
Deep Origin is attempting to create “virtual humans” that could one day reduce late-stage safety failures and the need for animal testing.
By Alexandra Pecci • July 16, 2026
